OriGene to Build mAb Production Facility in Wuxi

OriGene Technologies  announced plans to build one of the world’s largest monoclonal antibody production facilities in Wuxi, China. The center will be built “with the support” of the Wuxi Biopharmaceutical R&D Outsourcing Servicing Park, also known as BioPark. Specific details of the agreement were not disclosed. OriGene said the high-throughput production facility will eventually employ over one thousand people and have the capacity to produce more than 20,000 of the company’s TrueMAB™ antibodies per year. More details...